Matthew K. Szot, Chief Financial Officer at Cadrenal Therapeutics, Inc. (CVKD), sold 3,493 shares at $13.99 ($49K) on 2025-10-09, disclosed to the SEC on 2025-10-14.
Scheduled sale ($49k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.99 | 1,693 | $24K | 48.3% |
| 2 | $14.07 | 1,800 | $25K | 51.7% |
| Total | $14.03 avg | 3,493 | $49K | 100% |
| Filing → |
| SNES | SELL | 2025-11-17 | $3 | — | Filing → |
| CVKD | SELL | 2025-10-28 | $50K | — | Filing → |
| CVKD | SELL | 2025-10-07 | $1K | — | Filing → |